Resverlogix Confirms Focus on Treatment of Post COVID-19 ConditionsCALGARY, Alberta, Sept. 28, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix" or the “Company”) (TSX:RVX) today announced that apabetalone’s future clinical development related to COVID-19 will focus on the prevention and treatment of Post COVID-19 Conditions (PCC), colloquially known as long-COVID, as opposed to hospitalized COVID-19 patients, reflecting the compelling opportunity for apabetalone to benefit PCC patients and guidance from the US Food and Drug Administration (FDA).
The Power Play by The Market Herald Releases Interviews With Else Nutrition, Ayurcann Holdings, and ResverlogixVANCOUVER, BC / ACCESSWIRE / February 22, 2022 / The Power Play by The Market Herald has announced the release of new interviews with Else Nutrition, Ayurcann Holdings, and Resverlogix on their latest news. The Power Play by The Market Herald provides investors with a quick snapshot of what they need to know about the company's latest press release through exclusive insights and interviews with company executives. Else Nutrition (TSX:BABY)
Resverlogix: The Future of Drug Development, CEO Clip VideoVancouver, British Columbia--(Newsfile Corp. - December 16, 2021) - Resverlogix Corp. (TSX: RVX) - Donald McCaffrey, President & CEO speaks...
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Acquires Additional Securities of Resverlogix Corp.Calgary, Alberta--(Newsfile Corp. - May 21, 2021) - Shenzhen Hepalink Pharmaceutical Group Co., Ltd. ("Hepalink") announces that on May 13,...
